Co-occurring Mutations of Tumor Suppressor Genes, LATS2 and NF2 , in Malignant Pleural Mesothelioma - Archive ouverte HAL Access content directly
Journal Articles Clinical Cancer Research Year : 2017

Co-occurring Mutations of Tumor Suppressor Genes, LATS2 and NF2 , in Malignant Pleural Mesothelioma

(1, 2, 3, 4) , (1, 2, 4, 3) , (1) , (1, 2, 4, 3) , (1, 2, 4, 3) , (5) , (6) , (1, 2, 4, 3, 7, 8) , (1, 2, 4, 3, 8) , (1, 2, 4, 3) , (1, 2, 4, 3)
1
2
3
4
5
6
7
8
Anne Tallet
  • Function : Author
  • PersonId : 956871

Abstract

Purpose: To better define malignant pleural mesothelioma (MPM) heterogeneity and identify molecular subtypes of MPM, we focus on the tumor suppressor gene LATS2, a member of the Hippo signaling pathway, which plays a key role in mesothelial carcinogenesis.Experimental Design: Sixty-one MPM primary cultures established in our laboratory were screened for mutations in LATS2 Gene inactivation was modeled using siRNAs. Gene and protein expressions were analyzed by quantitative RT-PCR, Western blot analysis, and reverse phase protein array. Cell proliferation, viability, apoptosis, mobility, and invasion were determined after siRNA knockdown or YAP (verteporfin), mTOR (rapamycin), and mTOR/PI3K/AKT (PF-04691502) inhibitor treatment.Results: The LATS2 gene was altered in 11% of MPM by point mutations and large exon deletions. Genetic data coupled with transcriptomic data allowed the identification of a new MPM molecular subgroup, C2LN, characterized by a co-occurring mutation in the LATS2 and NF2 genes in the same MPM. MPM patients of this subgroup presented a poor prognosis. Coinactivation of LATS2 and NF2 leads to loss of cell contact inhibition between MPM cells. Hippo signaling pathway activity, mTOR expression, and phosphorylation were altered in the C2LN MPM subgroup. MPMs of this new subgroup show higher sensitivity to PF-04691502 inhibitor. The MOK gene was identified as a potential biomarker of the C2LN MPM subgroup and PF-04691502 sensitivity.Conclusions: We identified a new MPM molecular subgroup that shares common genetic and transcriptomic characteristics. Our results made it possible to highlight a greater sensitivity to an anticancer compound for this MPM subgroup and to identify a specific potential biomarker.
Fichier principal
Vignette du fichier
169740_1_merged_1479424427.pdf (2.76 Mo) Télécharger le fichier
Origin : Files produced by the author(s)
Loading...

Dates and versions

inserm-02478604 , version 1 (18-02-2020)

Identifiers

Cite

Robin Tranchant, Lisa Quetel, Anne Tallet, Clément Meiller, Annie Renier, et al.. Co-occurring Mutations of Tumor Suppressor Genes, LATS2 and NF2 , in Malignant Pleural Mesothelioma. Clinical Cancer Research, 2017, 23 (12), pp.3191-3202. ⟨10.1158/1078-0432.CCR-16-1971⟩. ⟨inserm-02478604⟩
87 View
86 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More